Condition: Dysphagia · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
This project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de l'Université de Montréal to improve therapeutic adherence and prevent dysphagia in patients treated with chemoradiotherapy for head and neck cancer. The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a patient partner. This intervention has the potential to improve quality of care, accessibility to services and optimize health care resources.
This description comes directly from the study's public registry record.
Marie-Eve Caty, M.P.O., Ph.D. · 819 376-5011 · marie-eve.caty@uqtr.ca
Houda Bahig, MD PhD · 514-890-8254 · houda.bahig.med@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de l'Université de Montréal | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05621889